Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

doi:10.1016/S1473-3099(17)30049-X

The Lancet Infectious Diseases

Volume 17, Issue 3, March 2017, Pages 313-321

https://doi.org/10.1016/S1473-3099(17)30049-X Get rights and content

Summary

Background

The serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal pneumonia has not been established in people aged 65 years or older. We assessed the effectiveness of PPV23 in this population.

Methods

For this multicentre, prospective study, we enrolled all individuals aged 65 years or older with community-onset pneumonia who visited four study hospitals in Japan between Sept 28, 2011, and Aug 23, 2014. Streptococcus pneumoniae was isolated from sputum and blood samples, and serotyped by the capsular Quellung method. Sputum samples were further tested by PCR assay to identify pneumococcal DNA, and positive samples were examined for 50 serotypes by a nanofluidic real-time PCR assay. Urine samples were tested by a urinary antigen test. Serotype-specific vaccine effectiveness was estimated using the test-negative design.

Findings

2621 eligible patients visited the study hospitals, of whom 585 did not have sputum samples available and were excluded from our analysis. 419 (21%) of 2036 patients were positive for pneumococcal infection (232 by sputum culture, 317 by sputum PCR, 197 by urinary antigen test, and 14 by blood culture). 522 (26%) patients were judged to be vaccinated in the analyses. Effectiveness of PPV23 was 27·4% (95% CI 3·2 to 45·6) against all pneumococcal pneumonia, 33·5% (5·6 to 53·1) against PPV23 serotypes, and 2·0% (−78·9 to 46·3) against non-PPV23 serotypes. Although no significant differences between subgroups were seen, higher protection was noted in people younger than 75 years, women, and individuals with lobar pneumonia or health-care-associated pneumonia.

Interpretation

PPV23 showed low to moderate effectiveness against vaccine serotype pneumococcal pneumonia in people aged 65 years or older. To improve the current pneumococcal vaccination programme, the variability of PPV23 effectiveness in different groups of older people must be further investigated.

Funding

Pfizer and Nagasaki University.

Introduction

Pneumococcal diseases, including pneumonia and invasive pneumococcal disease, are major causes of morbidity and mortality in older adults (aged ≥65 years) worldwide.1, 2, 3 Although invasive pneumococcal disease presents the most severe form with a high case fatality rate, pneumonia is the most common manifestation of pneumococcal disease in adults.⁴ The disease burden is rapidly increasing in many countries because of a higher risk in older age groups; therefore, the control of pneumococcal pneumonia is a public health priority in countries with an ageing population, such as Japan.⁵

To prevent pneumococcal disease, immunisation with 23-valent pneumococcal polysaccharide vaccine (PPV23) has been recommended for high-risk groups and older adults. Although there is good evidence that PPV23 reduces the risk of invasive pneumococcal disease in older people, its protective effect against pneumonia is controversial.6, 7, 8, 9 According to recent meta-analyses of trials and observational studies, the vaccine did not have a significant protective effect in preventing all-cause pneumonia and pneumococcal pneumonia.10, 11

Recently, a vaccine trial in the Netherlands (the CAPITA trial) showed the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) against vaccine serotype pneumococcal pneumonia and invasive pneumococcal disease in adults aged 65 years or older.¹² This finding has raised the question of whether PPV23 should be replaced by PCV13 in this group. Administration of both vaccines is currently recommended for this age group by the Advisory Committee on Immunization Practices in the USA,⁶ but the supporting evidence is insufficient. To our knowledge, no study has assessed the serotype-specific effect of PPV23 against pneumococcal pneumonia.

We did a multicentre, prospective study to elucidate the serotype-specific vaccine effectiveness of PPV23 against pneumococcal pneumonia in people aged 65 years or older in Japan. We did subgroup analyses to explore differences in vaccine effectiveness by population characteristics.

Research in context

Evidence before this study

A systematic review published in 2016 examined the evidence from randomised controlled trials that investigated the efficacy of 23-valent pneumococcal polysaccharide vaccine (PPV23) for preventing pneumococcal pneumonia in immunocompetent adults. The meta-analysis of three trials found a protective, but non-significant, trend. Findings from another systematic review published in 2016, which assessed evidence from observational studies, showed the effectiveness of PPV23 for prevention of community-acquired pneumonia. Nine cohort studies and seven case-control studies were identified, and the meta-analysis showed a non-significant protective effect of the vaccine. we searched PubMed for English language articles published between Jan 1, 1977, and July 20, 2016, with the terms “streptococcus pneumoniae”, “pneumococcus”, “pneumococcal”, “serotype”, “polysaccharide vaccine”, and “adult”. We also reviewed relevant articles identified in previous systematic reviews. This search retrieved no studies that investigated the serotype-specific efficacy or effectiveness of PPV23 against pneumococcal pneumonia.

Added value of this study

To our knowledge, our study is the first to investigate the serotype-specific effectiveness of PPV23 against pneumococcal pneumonia in older adults (aged ≥65 years). We report that the effectiveness of PPV23 against vaccine serotype pneumococcal pneumonia was low to moderate and differed by vaccine serotype, and that no protection was shown for non-vaccine serotypes. Although no significant differences between subgroups were seen, vaccine effectiveness was higher in specific groups such as people younger than 75 years, women, and individuals with lobar pneumonia or health-care-associated pneumonia.

Implications of all the available evidence

In view of the large number of older patients with pneumonia, the introduction of an effective pneumococcal vaccine for this age group could have a large public health impact. The currently recommended PPV23 prevents vaccine serotype pneumococcal pneumonia, but its effectiveness is low to moderate. Furthermore, the effects of PPV23 on pneumonia burden might lessen after the introduction of pneumococcal conjugate vaccine in children. For effective control of adult pneumococcal pneumonia, vaccine policy makers must monitor the proportion of vaccine serotypes in all cases of pneumococcal pneumonia and consider the variability of PPV23 effectiveness in different population groups.

Section snippets

Study design and participants

This study was done as part of a multicentre prospective investigation of adult pneumonia by the Adult Pneumonia Study Group-Japan (APSG-J).⁵ The APSG-J study was done at four community-based hospitals in Japan from Sept 28, 2011, to Aug 23, 2014. All inpatients and outpatients aged 15 years or older were screened for community-onset pneumonia by hospital physicians, and eligible patients were identified using a standardised case definition. To investigate the effectiveness of PPV23, we focused

Results

Between Sept 28, 2011, and Aug 23, 2014, 2621 patients aged 65 years or older with pneumonia visited the study hospitals. Sputum samples were not obtained from 585 patients (figure). Compared with patients whose sputum samples were available, patients whose sputum samples were not available were younger, more likely to live in the central part of Japan, more frequently treated as outpatients, and less frequently tested by urinary antigen test (appendix pp 3–4). After excluding these patients,

Discussion

In this study in older Japanese people, we found low to moderate effectiveness of PPV23 against vaccine serotype pneumococcal pneumonia, but no protective effect against non-vaccine serotypes. To our knowledge, this is the first study to show serotype-specific effectiveness of PPV23 against pneumococcal pneumonia in the general, older population.

PPV23 has been recommended for high-risk individuals and older adults in many countries; however, its protective effect has not been fully established.6

References (31)

WQ Diao et al.
Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials
Vaccine
(2016)
H Kraicer-Melamed et al.
The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis
Vaccine
(2016)
T Naito et al.
Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake
J Infect Chemother
(2014)
TL Wiemken et al.
The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study
Vaccine
(2014)
M Voysey et al.
Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells
Vaccine
(2016)
SL Klein et al.
The Xs and Y of immune responses to viral vaccines
Lancet Infect Dis
(2010)
T Welte et al.
Clinical and economic burden of community-acquired pneumonia among adults in Europe
Thorax
(2012)
L Peto et al.
The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review
Trans R Soc Trop Med Hyg
(2014)
S Jain et al.
Community-acquired pneumonia requiring hospitalization among U.S. adults
N Engl J Med
(2015)
MA Said et al.
Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques
PLoS One
(2013)

K Morimoto et al.

The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study

PLoS One

(2015)

S Tomczyk et al.

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)

MMWR Morb Mortal Wkly Rep

(2014)

A Huss et al.

Efficacy of pneumococcal vaccination in adults: a meta-analysis

CMAJ

(2009)

S Moberley et al.

Vaccines for preventing pneumococcal infection in adults

Cochrane Database Syst Rev

(2013)

LA Jackson et al.

Effectiveness of pneumococcal polysaccharide vaccine in older adults

N Engl J Med

(2003)

Cited by (143)

Clinical characteristics and antimicrobial susceptibility of non-vaccine serotype Streptococcus pneumoniae in adult Japanese patients with pneumonia
2024, Journal of Infection and Chemotherapy
Non-vaccine serotype (NVT) pneumococcal pneumonia in Japan has increased with the spread of pneumococcal vaccinations. However, there is no data regarding the clinical background and antimicrobial susceptibility of NVT isolates compared with those of vaccine serotype (VT) isolates in adult pneumococcal pneumonia.
The serotypes and antimicrobial susceptibilities of pneumococcal isolates obtained from patients with pneumonia at the University of Occupational and Environmental Health, Japan, from January 2011 to December 2020 were retrospectively evaluated along with the patients’ clinical information.
In total, 252 patients with pneumococcal pneumonia (98 NVT and 154 VT isolates) were included. Among NVTs, the most common serotype was 35B, followed by 15A, 34, 6C, 23A, and 15C. The MIC₅₀ and MIC₉₀ of each antibiotic in 35B and 15A tend to be higher than those in 34, 6C, and 23A. Regarding background characteristics, the percentages of patients with dementia and liver disease were significantly higher in patients in the VT group than in those in the NVT group (p = 0.048 and p = 0.012, respectively). There were no significant differences in the severity of pneumonia and mortality rate between patients with the VT and NVT isolates. This study first demonstrated that NVT isolates included those with reduced susceptibility to antibiotics in adult pneumonia in Japan. The data of the present study can be useful in optimizing treatment strategies for pneumococcal pneumonia because of the increasing number of NVT cases in Japan.
Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study
2024, Vaccine
Little is known about the impact of physical activity (PA) and PPSV23 vaccination on pneumonia-related hospitalizations. This study examined the association between regular PA and pneumonia-related hospitalization according to PPSV23 vaccination status in older adults.
This retrospective cohort study was conducted using health checkup data, medical care claims data, and vaccination records from two Japanese municipalities. Residents aged ≥65 years who had undergone a health checkup between April 2016 and March 2021 were categorized into a PPSV23 vaccinated or unvaccinated cohort. Each cohort was further divided into a PA group and no PA group. The hazard ratio (HR) of PA for pneumonia-related hospitalization was calculated for each cohort while adjusting for sex, age, comorbidities, and metabolic syndrome.
The vaccinated cohort comprised 16,295 participants (no PA: 5,139, PA: 11,156), and the unvaccinated cohort comprised 7,998 participants (no PA: 2,671, PA: 5,327). In the vaccinated cohort, the PA group had a significantly lower hazard for pneumonia-related hospitalization than the no PA group (adjusted HR: 0.58, P = 0.004). However, PA was not associated with pneumonia-related hospitalization in the unvaccinated cohort (adjusted HR: 0.70, P = 0.270).
PA can reduce the risk of pneumonia-related hospitalization in vaccinated persons. Interventions that increase both vaccination rates and PA habits may help to reduce these hospitalizations in older adults.
Excess mortality among people with communicable diseases over a 30-year period, Victoria, Australia: a whole of population cohort study
2023, The Lancet Regional Health - Western Pacific
Understanding mortality burden associated with communicable diseases is key to informing resource allocation, disease prevention and control efforts, and evaluating public health interventions. We quantified excess mortality among people notified with communicable diseases in Victoria, Australia.
Cases of communicable disease notified in Victoria between 1 January 1991 and 31 December 2021 were linked to the death registry. Informational gain obtained through linkage and 30-day case fatality rates were calculated for each disease. Standardised mortality ratios (SMR) and 95% confidence intervals were calculated up to a year following illness onset.
There were 1,032,619 cases and 5985 (0.58%) died ≤30 days of illness onset. Following linkage, the 30-day case fatality rate increased more than 2-fold. Diseases with high 7-day SMR signifying excess mortality included invasive pneumococcal disease (167.7, 95% CI 153.4–182.7); listeriosis (166.2, 95% CI 121.2–218.3); invasive meningococcal disease (145.9, 95% CI 116.7–178.3); legionellosis (43.3, 95% CI 28.0–62.0); and COVID-19 (21.9, 95% CI 19.7–24.3). Most diseases exhibited a strong negative gradient, with high SMRs in the first 7-days of illness onset that reduced over time.
We demonstrated that the rate of death in Victoria's notifiable disease surveillance dataset is underestimated. Further, compared to a general population, there is evidence of elevated all-cause mortality among people notified with communicable diseases often up to one year following illness onset. Not all elevated risk is likely directly attributable to the communicable diseases of interest, rather, it may reflect underlying comorbidities or behaviours in these individuals. Regardless of attribution, infection with communicable diseases may represent a marker of mortality. Key to preventing deaths may be through timely and appropriate transition to primary and preventive healthcare following diagnosis.
No funding was provided for this study.
Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain
2023, Vaccine
A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).
A Markov model, with annual cycles and a time horizon of 10 years was used. The analysis population was stratified by age and risk groups. The comparator was the sequential vaccination with the 15-valent pneumococcal conjugate vaccine (PCV15) followed by one dose of the pneumococcal polysaccharide vaccine (PPV23). The base case analysis was performed from the National Healthcare System (NHS) perspective including direct costs (€2018) and applying a discount of 3% to future costs and outcomes. Alternative scenarios explored a shorter time horizon (5 years), the societal perspective and other available vaccination strategies. All the parameters and assumptions were validated by a panel of experts. To evaluate the robustness of the model, deterministic and probabilistic sensitivity analyses (PSA) were carried out.
The results of the study showed that the vaccination strategy with PCV20 is a dominant option compared to the sequential regimen (PCV15 + PPSV23), resulting in direct cost savings of €85.7 M over 10 years, with a small increase in quality-adjusted life years (QALYs). PCV20 vaccination avoided 2,161 cases of IPD, 19,470 of NBP and 3,396 deaths and according to the PSA, the probability of PCV20 being cost-effective compared to a sequential regimen (PCV15 + PPSV23) was 100%.
In the Spanish adult population older than 60 years, the vaccination strategy with one dose of PCV20 is more effective and less expensive (dominant) than vaccination with a sequential schedule with PCV15 and PPSV23.
Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan
2023, Clinical Microbiology and Infection
The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in preventing pneumonia in older adults remains controversial. Some studies have suggested differences in their effectiveness according to age or sex.
We conducted an observational study using a database of vaccine subsidization data and health insurance claims for a city in Japan. Participants were residents from 2014 to 2018 turning 65, 70, 75, 80, 85, 90, or 95 years during a given fiscal year, and PPV23 during the first year of observation were identified. We matched vaccinated and non-vaccinated individuals of the same age using propensity scores for vaccination. The incidence of hospitalization with pneumonia was compared using the Fine-Gray regression model. We summarized the results for each age using random-effects meta-analysis and conducted a subgroup analysis by sex.
A total of 102 136 participants were included, of whom 35% received PPV23. Propensity score matching selected 32 510 pairs of vaccinated and non-vaccinated individuals. Overall, PPV23 administration was associated with a decreased incidence of hospitalization with pneumonia (17.2 vs. 20.4 per 1000 person-years, sub-distribution hazard ratio: 0.84, 95% CI: 0.77 to 0.91). Vaccine effectiveness was the highest among those aged 70 years and decreased with increasing age. No statistically significant effect was observed in those aged 90 or 95 years. Vaccine effectiveness was observed in both males and females.
PPV23 was associated with an overall decrease in hospitalization with pneumonia in older adults. However, vaccine effectiveness was significant in those aged 65 to 85 years but not in the older population.
Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study
2023, Vaccine
We aimed to assess the cost-effectiveness and health benefits of 23-valent pneumococcal polysaccharide vaccine (PPSV23), 13-valent pneumococcal conjunctive vaccine (PCV13), and PCV13-PPSV23 sequential vaccination strategies in preventing pneumonia and other pneumococcal diseases among the senior citizens ( $\geq$ 65 years) in China. The cost-effectiveness of pneumococcal vaccines compared to no vaccination was estimated using a decision-tree Markov model from a societal perspective. Parameters including epidemiological data, vaccine efficacy and cost data were obtained from previous studies. Cases and deaths averted, quality-adjusted life years (QALYs) gained, and incremental cost-effectiveness ratios (ICERs) were presented as outcomes. Sensitivity analyses were performed to explore the uncertainty in the model. In the base-case analysis, compared with no pneumococcal vaccination, the ICERs of PPSV23, PCV13 and PCV13-PPSV23 are US$10,776.7/QALY, $9,193.2/QALY, and $15,080.0/QALY, respectively. PCV13 is the most cost-effective strategy and the only cost-effective strategy based on a threshold of the one-time national GDP per capita, whereas PPSV23 vaccine strategy is provided with the lowest cost, and PCV13-PPSV23 demonstrates the greatest impact on pneumococcal disease burden. Sensitivity analyses reveal that the results are greatly influenced by serotype coverage, vaccine efficacy, CAP incidence and vaccine prices. The PCV13 vaccination for Chinese seniors is more cost-effective than PPSV23 vaccination and PCV13-PPSV23 sequential vaccination.

View all citing articles on Scopus

^†: Members listed at end of paper

View full text

ArticlesSerotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

Summary

Background

Methods

Findings

Interpretation

Funding

Introduction

Section snippets

Study design and participants

Results

Discussion

Vaccine

Vaccine

J Infect Chemother

Vaccine

Vaccine

Lancet Infect Dis

Clinical and economic burden of community-acquired pneumonia among adults in Europe

Thorax

The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review

Trans R Soc Trop Med Hyg

Community-acquired pneumonia requiring hospitalization among U.S. adults

N Engl J Med

Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques

PLoS One

The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study

PLoS One

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)

MMWR Morb Mortal Wkly Rep

Efficacy of pneumococcal vaccination in adults: a meta-analysis

CMAJ

Vaccines for preventing pneumococcal infection in adults

Cochrane Database Syst Rev

Effectiveness of pneumococcal polysaccharide vaccine in older adults

N Engl J Med

Articles
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study